S&P 500   3,377.05 (+0.49%)
DOW   28,072.65 (+1.01%)
QQQ   269.87 (-0.16%)
AAPL   446.85 (-0.90%)
MSFT   207.28 (-0.47%)
FB   265.11 (+0.80%)
GOOGL   1,507.62 (+0.72%)
AMZN   3,150.66 (+0.08%)
NVDA   443.08 (-0.79%)
CGC   17.62 (-1.73%)
BABA   252.17 (+1.62%)
TSLA   1,414.53 (-0.28%)
GE   6.86 (+2.85%)
MU   48.69 (-0.94%)
AMD   79.88 (-2.87%)
T   30.36 (+0.53%)
F   7.27 (+2.54%)
ACB   10.10 (-1.17%)
GILD   68.36 (-0.22%)
NFLX   477.47 (-1.22%)
DIS   131.29 (+1.94%)
BAC   27.32 (+2.86%)
BA   185.80 (+3.56%)
S&P 500   3,377.05 (+0.49%)
DOW   28,072.65 (+1.01%)
QQQ   269.87 (-0.16%)
AAPL   446.85 (-0.90%)
MSFT   207.28 (-0.47%)
FB   265.11 (+0.80%)
GOOGL   1,507.62 (+0.72%)
AMZN   3,150.66 (+0.08%)
NVDA   443.08 (-0.79%)
CGC   17.62 (-1.73%)
BABA   252.17 (+1.62%)
TSLA   1,414.53 (-0.28%)
GE   6.86 (+2.85%)
MU   48.69 (-0.94%)
AMD   79.88 (-2.87%)
T   30.36 (+0.53%)
F   7.27 (+2.54%)
ACB   10.10 (-1.17%)
GILD   68.36 (-0.22%)
NFLX   477.47 (-1.22%)
DIS   131.29 (+1.94%)
BAC   27.32 (+2.86%)
BA   185.80 (+3.56%)
S&P 500   3,377.05 (+0.49%)
DOW   28,072.65 (+1.01%)
QQQ   269.87 (-0.16%)
AAPL   446.85 (-0.90%)
MSFT   207.28 (-0.47%)
FB   265.11 (+0.80%)
GOOGL   1,507.62 (+0.72%)
AMZN   3,150.66 (+0.08%)
NVDA   443.08 (-0.79%)
CGC   17.62 (-1.73%)
BABA   252.17 (+1.62%)
TSLA   1,414.53 (-0.28%)
GE   6.86 (+2.85%)
MU   48.69 (-0.94%)
AMD   79.88 (-2.87%)
T   30.36 (+0.53%)
F   7.27 (+2.54%)
ACB   10.10 (-1.17%)
GILD   68.36 (-0.22%)
NFLX   477.47 (-1.22%)
DIS   131.29 (+1.94%)
BAC   27.32 (+2.86%)
BA   185.80 (+3.56%)
S&P 500   3,377.05 (+0.49%)
DOW   28,072.65 (+1.01%)
QQQ   269.87 (-0.16%)
AAPL   446.85 (-0.90%)
MSFT   207.28 (-0.47%)
FB   265.11 (+0.80%)
GOOGL   1,507.62 (+0.72%)
AMZN   3,150.66 (+0.08%)
NVDA   443.08 (-0.79%)
CGC   17.62 (-1.73%)
BABA   252.17 (+1.62%)
TSLA   1,414.53 (-0.28%)
GE   6.86 (+2.85%)
MU   48.69 (-0.94%)
AMD   79.88 (-2.87%)
T   30.36 (+0.53%)
F   7.27 (+2.54%)
ACB   10.10 (-1.17%)
GILD   68.36 (-0.22%)
NFLX   477.47 (-1.22%)
DIS   131.29 (+1.94%)
BAC   27.32 (+2.86%)
BA   185.80 (+3.56%)
Log in

NASDAQ:BCRXBioCryst Pharmaceuticals Stock Price, Forecast & News

$4.12
0.00 (0.00 %)
(As of 08/11/2020 12:26 PM ET)
Add
Compare
Today's Range
$4.05
Now: $4.13
$4.19
50-Day Range
$3.89
MA: $4.66
$5.44
52-Week Range
$1.38
Now: $4.13
$6.29
Volume2.84 million shs
Average Volume6.55 million shs
Market Capitalization$727.65 million
P/E RatioN/A
Dividend YieldN/A
Beta2.77
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Read More
BioCryst Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.71 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BCRX
CUSIP09058V10
Phone919-859-1302

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$48.83 million
Book Value$0.26 per share

Profitability

Net Income$-108,900,000.00
Net Margins-236.65%
Return on Equity-53,981.51%

Miscellaneous

Employees100
Market Cap$727.65 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$4.12
0.00 (0.00 %)
(As of 08/11/2020 12:26 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BioCryst Pharmaceuticals (NASDAQ:BCRX) Frequently Asked Questions

How has BioCryst Pharmaceuticals' stock been impacted by Coronavirus?

BioCryst Pharmaceuticals' stock was trading at $2.59 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BCRX shares have increased by 58.9% and is now trading at $4.1150.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of BioCryst Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BioCryst Pharmaceuticals
.

When is BioCryst Pharmaceuticals' next earnings date?

BioCryst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for BioCryst Pharmaceuticals
.

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) posted its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.04. The biotechnology company earned $2.87 million during the quarter, compared to analysts' expectations of $3.17 million. BioCryst Pharmaceuticals had a negative return on equity of 53,981.51% and a negative net margin of 236.65%.
View BioCryst Pharmaceuticals' earnings history
.

What price target have analysts set for BCRX?

8 equities research analysts have issued twelve-month price objectives for BioCryst Pharmaceuticals' shares. Their forecasts range from $4.00 to $13.00. On average, they expect BioCryst Pharmaceuticals' stock price to reach $8.33 in the next twelve months. This suggests a possible upside of 102.5% from the stock's current price.
View analysts' price targets for BioCryst Pharmaceuticals
.

Has BioCryst Pharmaceuticals been receiving favorable news coverage?

Media stories about BCRX stock have trended neutral on Tuesday, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioCryst Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about BioCryst Pharmaceuticals
.

Are investors shorting BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 18,000,000 shares, an increase of 31.4% from the December 15th total of 13,700,000 shares. Based on an average daily trading volume, of 2,810,000 shares, the days-to-cover ratio is currently 6.4 days.
View BioCryst Pharmaceuticals' Short Interest
.

Who are some of BioCryst Pharmaceuticals' key competitors?

What other stocks do shareholders of BioCryst Pharmaceuticals own?

Who are BioCryst Pharmaceuticals' key executives?

BioCryst Pharmaceuticals' management team includes the following people:
  • Mr. Jon P. Stonehouse, CEO, Pres & Director (Age 58)
  • Mr. Thomas R. Staab II, CFO, Principal Accounting Officer, Sr. VP & Treasurer (Age 51)
  • Dr. William P. Sheridan, Chief Medical Officer & Sr. VP (Age 64)
  • Dr. Yarlagadda S. Babu, Sr. VP of Drug Discovery (Age 66)
  • Ms. Lynne M. Powell, Chief Commercial Officer & Sr. VP (Age 52)

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

Who are BioCryst Pharmaceuticals' major shareholders?

BioCryst Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include SG Americas Securities LLC (0.53%), Platinum Investment Management Ltd. (0.26%), Swiss National Bank (0.22%), Assenagon Asset Management S.A. (0.17%), Rafferty Asset Management LLC (0.13%) and Edge Wealth Management LLC (0.11%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Jon P Stonehouse, Kenneth B Lee Jr, Lynne Powell, Megan Sniecinski, Steve Aselage, Thomas R Staab II and William P Sheridan.
View institutional ownership trends for BioCryst Pharmaceuticals
.

Which major investors are selling BioCryst Pharmaceuticals stock?

BCRX stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Platinum Investment Management Ltd., Virtus ETF Advisers LLC, and Personal CFO Solutions LLC.
View insider buying and selling activity for BioCryst Pharmaceuticals
.

Which major investors are buying BioCryst Pharmaceuticals stock?

BCRX stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Assenagon Asset Management S.A., Rafferty Asset Management LLC, Edge Wealth Management LLC, Swiss National Bank, Leap Investments LP, Cambridge Investment Research Advisors Inc., and North Star Investment Management Corp.. Company insiders that have bought BioCryst Pharmaceuticals stock in the last two years include Alane P Barnes, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski, and Steve Aselage.
View insider buying and selling activity for BioCryst Pharmaceuticals
.

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioCryst Pharmaceuticals' stock price today?

One share of BCRX stock can currently be purchased for approximately $4.12.

How big of a company is BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals has a market capitalization of $725.89 million and generates $48.83 million in revenue each year. The biotechnology company earns $-108,900,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. BioCryst Pharmaceuticals employs 100 workers across the globe.

What is BioCryst Pharmaceuticals' official website?

The official website for BioCryst Pharmaceuticals is www.biocryst.com.

How can I contact BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at 919-859-1302 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.